Financing for a new investment in production and research capacity
On May 17, 2023, Antibiotice SA, the most important Romanian manufacturer of generic drugs obtained, following the call for projects financed by GD 807/2014 for the establishment of a State aid scheme aimed at stimulating investments with a major impact on the economy, the agreement for financing the project “Capacity for the production, packaging and storage of sterile products, solutions and topical”.
The total value of the project is 200,101,617 lei, of which the state aid is worth 85,002,772 million lei, the rest being provided from own resources.
This investment is part of the Company’s Strategic Development Plan “The Future together 2020-2030”, which aims to multiply profits, of turnover with an impact on the increase of market shares held by Antibiotice on the local and international market.
Future production and logistics capacity will ensure the manufacture of new valuable generic medicines, by approaching new pharmaceutical forms, respectively sterile solutions for injection and sterile topical products.
The company thus uses expertise in the manufacture of sterile injectable powders by approaching a new segment of medicines for hospitals (sterile solutions dosed in glass bottles), as well as dermatological and ophthalmic disorders (sterile topical). The manufacture of these new types of medicines will strategically contribute to supporting the national health system and increasing exports, with an impact on the increase in turnover in the 2030s.
At the same time, by implementing this investment, the 1350 existing jobs on the platform will be strengthened, setting up new jobs, especially in the field of product research and development. We mention that the investment is part of the 85 projects considered a priority in the Strategy for Regional Research and Innovation through smart specialization (RIS 3 North-East), which will ensure the development of the North-East Region.
